ACE2-IgG1 fusions with improved in vitro and in vivo activity against SARS-CoV-2

ACE2-IgG1 fusions with improved in vitro and in vivo activity against SARS-CoV-2

Summary: SARS-CoV-2, the etiologic agent of COVID-19, uses ACE2 as a cell entry receptor. Soluble ACE2 has been shown to have neutralizing antiviral activity but has a short half-life and no active transport mechanism from the circulation into the alveolar spaces of the lung. To overcome this, we co...

Full description

Bibliographic Details
Main Authors: Naoki Iwanaga, Laura Cooper, Lijun Rong, Nicholas J. Maness, Brandon Beddingfield, Zhongnan Qin, Jackelyn Crabtree, Ralph A. Tripp, Haoran Yang, Robert Blair, Sonia Jangra, Adolfo García-Sastre, Michael Schotsaert, Sruti Chandra, James E. Robinson, Akhilesh Srivastava, Felix Rabito, Xuebin Qin, Jay K. Kolls
Format: Article
Language:English
Published: Elsevier 2022-01-01
Series:iScience
Subjects:
Drugs
Virology
Online Access:http://www.sciencedirect.com/science/article/pii/S2589004221016400

Internet

http://www.sciencedirect.com/science/article/pii/S2589004221016400

Similar Items